Yan Zhang

Dr. Yan Zhang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2025 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MCMinyuan Cao
Minyuan Cao
YDYun Deng
Yun Deng
QHQing Hao
Qing Hao
HYHuayun Yan
Huayun Yan
QWQuan-Lin Wang
Quan-Lin Wang
HXHeng Xu
Heng Xu
The gut microbiota crucially regulates the efficacy of immune checkpoint inhibitor (ICI) based immunotherapy, but the underlying mechanisms remain unclear at the single-cell resolution. Using single-cell RNA sequencing and subsequent validations, we investigate gut microbiota-ICI synergy by profiling the tumor microenvironment (TME) and elucidating critical cellular interactions in mouse models. Our findings reveal that intact gut microbiota combined with ICIs may synergistically increase the proportions of CD8 +, CD4 +, and γδ T cells, reduce glycolysis metabolism, and reverse exhausted CD8 + T cells into memory/effector CD8 + T cells, enhancing antitumor response. This synergistic effect also induces macrophage reprogramming from M2 protumor Spp1 + tumor-associated macrophages (TAMs) to Cd74 + TAMs, which act as antigen-presenting cells (APCs). These macrophage subtypes show a negative correlation within tumors, particularly during fecal microbiota transplantation. Depleting Spp1 + TAMs in Spp1 conditional knockout mice boosts ICI efficacy and T cell infiltration, regardless of gut microbiota status, suggesting a potential upstream role of the gut microbiota and highlighting the crucial negative impact of Spp1 + TAMs during macrophage reprogramming on immunotherapy outcomes. Mechanistically, we propose a γδ T cell-APC-CD8 + T cell axis, where gut microbiota and ICIs enhance Cd40lg expression on γδ T cells, activating Cd40 overexpressing APCs (e.g., Cd74 + TAMs) through CD40-CD40L-related NF-κB signaling and boosting CD8 + T cell responses via CD86-CD28 interactions. These findings highlight the potential importance of γδ T cells and SPP1-related macrophage reprogramming in activating CD8 + T cells, as well as the synergistic effect of gut microbiota and ICIs in immunotherapy through modulating the TME.

15 August 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
XZXiaojuan Zhou
Xiaojuan Zhou
LZLaiyan Zhou
Laiyan Zhou
ZYZhuoran Yao
Zhuoran Yao
MHMeijuan Huang
Meijuan Huang
YGYouling Gong
Youling Gong
JXjianxin xue
jianxin xue
Purpose: Low-dose radiotherapy (LDRT) may enhance the synergistic antitumor effect of combined immunotherapy and stereotactic body radiotherapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluated for the first time as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC). Patients and Methods: This prospective phase I study enrolled 29 patients and included a dose-escalation and dose-expansion phase. Patients received SBRT [30 Gray (Gy)/3f] to small lesions and LDRT (2 Gy/1f, 4 Gy/2f, or 10 Gy/5f) to a large lesion concurrently, followed by sintilimab (a programmed death-1 inhibitor). The primary endpoint was safety and tolerability; secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: No dose-limiting toxicities were observed during the dose-escalation phase; 4 Gy/2f was the recommended LDRT dose. Median follow-up was 15.6 months. Treatment-related adverse events (TRAE) occurred in 96.6% (28/29) of patients [grade ≥ 3; 20.7% (6/29)]; 2 patients (6.9%) discontinued due to TRAEs. Seven patients experienced pneumonitis (grade 2, n = 6; grade 3, n = 1). Immune-related adverse events were noted in 58.6% (17/29) of patients. In patients with tumor assessment (n = 28), ORR and confirmed ORR were 60.7% and 57.1%, respectively. Median PFS was 8.6 months (95% confidence interval, 3.7–16.5), and median OS was not reached. Exploratory analyses suggested both expanded and newly emerging T-cell receptor clonotypes were associated with better PFS. Conclusions: The findings indicate that the novel SBRT + LDRT + sintilimab therapy is safe and promising in patients with programmed death ligand-1–positive, driver gene–negative primary metastatic NSCLC.

1 November 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JYjinji yang
jinji yang
YZYan Zhang
Yan Zhang
LWLin Wu
Lin Wu
JHJie Hu
Jie Hu
ZWZhe-Hai Wang
Zhe-Hai Wang
YWYI-LONG WU
YI-LONG WU
PURPOSE: The KUNPENG study aimed to evaluate the efficacy and safety of vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition ( MET ), in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring c-Met alterations. METHODS: This multicenter, multicohort, open-label, single-arm, phase II trial enrolled patients with c-Met dysregulated, locally advanced or metastatic NSCLC from January 2020 to August 2022 across 17 centers. Cohort 1 included patients with MET exon 14 skipping ( MET ex14)–mutant NSCLC who had not previously received MET inhibitors. Participants were administered vebreltinib at a dosage of 200 mg twice a day in 28-day cycles. The primary end point was the objective response rate (ORR), and the key secondary end point was the duration of response (DoR), both evaluated by a blinded independent review committee according to the RECIST version 1.1. RESULTS: As of August 9, 2022, 52 patients had been enrolled in cohort 1, of whom 35 (67.3%) were treatment-naïve. The ORR reached 75% (95% CI, 61.1 to 86). Among treatment-naïve patients, the ORR was 77.1% (95% CI, 59.9 to 89.6), and in previously treated patients, it was 70.6% (95% CI, 44.0 to 89.7). The disease control rate was 96.2%, with a median DoR of 15.9 months, a median progression-free survival of 14.1 months, and a median overall survival of 20.7 months. The most common treatment-related adverse events were peripheral edema (82.7%), QT prolongation (30.8%), and elevated serum creatinine (28.8%). CONCLUSION: Vebreltinib has shown promising efficacy and a favorable safety profile in patients with MET ex14-mutant NSCLC.

20 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
JKJingyue Kang
Jingyue Kang
TSTonglin Sun
Tonglin Sun
YZYan Zhang
Yan Zhang
Bispecific antibodies (bsAbs) are artificial antibodies with two distinct antigen-binding sites that can bind to different antigens or different epitopes on the same antigen. Based on a variety of technology platforms currently developed, bsAbs can exhibit different formats and mechanisms of action. The upgrading of antibody technology has promoted the development of bsAbs, which has been effectively used in the treatment of tumors. So far, 7 bsAbs have been approved for marketing in the world, and more than 200 bsAbs are in clinical and preclinical research stages. Here, we summarize the development process of bsAbs, application in tumor treatment and look forward to the challenges in future development.

15 December 2023 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
CJCongcong Jian
Congcong Jian
LWLingli Wei
Lingli Wei
TWTong Wu
Tong Wu
SLShilin Li
Shilin Li
TWTingting Wang
Tingting Wang
FZFanxin Zeng
Fanxin Zeng
Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease with complex causes and recurrent attacks that can easily develop into chronic arthritis and eventually lead to joint deformity. Our study aims to elucidate potential mechanism among control, new-onset RA (NORA) and chronic RA (CRA) with multi-omics analysis. Methods: A total of 113 RA patients and 75 controls were included in our study. Plasma and stool samples were obtained for 16S rRNA sequencing, internally transcribed spacer (ITS) sequencing and metabolomics analysis. And PBMCs were obtained for RNA sequencing. We used three models, logistic regression, least absolute shrinkage and selection operator (LASSO), and random forest, respectively, to distinguish NORA from CRA, and finally we validated model performance using an external cohort of 26 subjects. Results: Our results demonstrated intestinal flora disturbance in RA development, with significantly increased abundance of Escherichia-Shigella and Proteobacteria in NORA. We also found that the diversity was significantly reduced in CRA compared to NORA through fungi analysis. Moreover, we identified 29 differential metabolites between NORA and CRA. Pathway enrichment analysis revealed significant dysregulation of glycerophospholipid metabolism and phenylalanine metabolism pathways in RA patients. Next, we identified 40 differentially expressed genes between NORA and CRA, which acetylcholinesterase (ACHE) was the core gene and significantly enriched in glycerophospholipid metabolism pathway. Correlation analysis showed a strong negatively correlation between glycerophosphocholine and inflammatory characteristics. Additionally, we applied three approaches to develop disease classifier models that were based on plasma metabolites and gut microbiota, which effectively distinguished between new-onset and chronic RA patients in both discovery cohort and external validation cohort. Conclusions: These findings revealed that glycerophospholipid metabolism plays a crucial role in the development and progression of RA, providing new ideas for early clinical diagnosis and optimizing treatment strategies.

1 July 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
MXMinqin Xiao
Minqin Xiao
YDYiqi Deng
Yiqi Deng
HGHang Guo
Hang Guo
ZRZhixiang Ren
Zhixiang Ren
YHYajiao He
Yajiao He
LWLanlan Wang
Lanlan Wang
Background: Non-small cell lung cancer (NSCLC) remains one of the most prevalent malignancies. A series of differentially expressed genes (DEGs) have been identified in tumor samples and play critical roles in modulating the characteristics of tumor cells. However, some DEGs are specifically expressed in the tumor microenvironment (TME) cells. The underlying mechanisms of the functional DEGs warrant comprehensive investigation to elucidate their contributions to tumor biology of NSCLC. Therefore, the primary goal of our study is to systematically investigate TME-related DEGs using NSCLC as a model. Methods: DEG analysis was performed by comparing bulk transcriptomes of adjacent and tumor samples across 7 independent NSCLC cohorts. Expression pattern of these DEGs were annotated to specific cell types using a single-cell RNA sequencing (scRNA-seq) dataset from 13 NSCLC studies. Myeloid and stromal cells were re-clustered to achieve a detailed characterization of cell-cell interactions within the TME. Spatial co-localization of distinct subpopulations was validated by immunofluorescence staining and spatial transcriptomics (ST). Finally, functional relevance of these interactions was evaluated using a conditional knockout mouse model. Results: A total of 82 overlapping DEGs were screened out using bulk transcriptomes across 7 NSCLC cohorts. After clustering the integrated 547,360 cells from 217 adjacent/tumor NSCLC samples with available scRNA-seq data, we observed that most of these DEGs were specifically expressed in epithelial, myeloid, and stromal cells. Notably, SPP1 ranks the top DEG and is specifically expressed in myeloid cells. The elevated SPP1 expression in bulk transcriptome was attributed to both enriched proportion of SPP1+ macrophages and increased expression level of SPP1 in such myeloid subcluster in NSCLC tumor, which was potentially regulated by several transcriptional factors (e.g., HIF1A, ATF5, and STAT1). Cell-cell communication analysis indicated FAP+ fibroblasts exhibited the strongest interaction with SPP1+ macrophages within TME. Multiple fluorescent staining demonstrated significantly increased SPP1+ macrophage and FAP+ fibroblast interactions in tumor compared to adjacent tissues. Nichnet analysis showed VCAN-ITGB1 ligand-receptor axis mediating this cellular interaction. ST analysis revealed that this interaction established an immune-excluding barrier surrounding the tumor core. In addition, immune cells (CD4+/CD8+ T and NK cell) were recruited to tumor edge. Consistently, macrophage-specific Spp1 knockout in a mouse model resulted in increased CD3+ and CD8+ T cell infiltration and reduced subcutaneous tumor size. Clinically, patients with FAPHighSPP1High expression in tumor exhibited significantly poor prognosis for immunotherapy treatment. Conclusions: SPP1 ranks as the top DEG in NSCLC tumor attributed to its specific expression in SPP1+ macrophages, proportion of which increases in tumor and interact with FAP+ fibroblasts. Their interactions contribute to the formation of a tumor barrier that inhibits immune infiltration, reducing the immunotherapy efficacy in NSCLC.